TY - JOUR
T1 - Risk evaluation for the development of cervical intraepithelial neoplasia
T2 - Development and validation of risk-scoring schemes
AU - Lee, Chien Hung
AU - Peng, Chiung Yu
AU - Li, Ruei Nian
AU - Chen, Yu Chieh
AU - Tsai, Hsiu Ting
AU - Hung, Yu Hsiu
AU - Chan, Te Fu
AU - Huang, Hsiao Ling
AU - Lai, Tai Cheng
AU - Wu, Ming Tsang
N1 - Publisher Copyright:
© 2014 UICC.
PY - 2015/1/15
Y1 - 2015/1/15
N2 - Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk-scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community-based case-control data (n = 1523). By calculating the area under the receiver operating characteristic (AU-ROC) curve, these schemes were validated in a Papanicolaou smear follow-up cohort (n = 967) and a hospital-based cytology screening population (n = 217). A high DNA load of high-risk human papillomavirus (HR-HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV-testing-contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU-ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3- and 5-year follow-ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital-based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3- and 5-year cumulative incidence, respectively, and a 40.5-fold hazard ratio of developing CIN2+. In conclusion, combined with HR-HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high-risk human papillomavirus (HR-HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR-HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR-HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk-scoring. The CRS scheme was especially useful for CIN2+ screening.
AB - Cervical cancer screening guidelines do not comprehensively define what constitutes high risk. This study developed and validated simple risk-scoring schemes to improve Papanicolaou smear screening for women at high risk. Four cumulative risk score (CRS) schemes were derived respectively for the development of cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 or worse (CIN2+) using community-based case-control data (n = 1523). By calculating the area under the receiver operating characteristic (AU-ROC) curve, these schemes were validated in a Papanicolaou smear follow-up cohort (n = 967) and a hospital-based cytology screening population (n = 217). A high DNA load of high-risk human papillomavirus (HR-HPV) was the main predictor for CIN1 and CIN2+, although age, married status combined with the number of sexual partners, active and passive smoking and age at sexual debut also affected associated lesions. In the training set, only the HPV-testing-contained CIN2+ CRS scheme presented an excellent discrimination for identifying CIN2+ (AU-ROC = 0.866). Using a CRS cutoff value of 4 to identify CIN2+, the sensitivity and specificity of predicting CIN2+ for the 3- and 5-year follow-ups were 100% and 90.8%, and 83.3% and 90.4%, respectively, in the validation cohort. In the hospital-based validation population, the CRS scheme showed comparable discrimination for CIN2+ detection (sensitivity 88.2% and specificity 84.6%). Women with CRS ≥4 had a 5.4% and 9.1% of 3- and 5-year cumulative incidence, respectively, and a 40.5-fold hazard ratio of developing CIN2+. In conclusion, combined with HR-HPV testing and verified risk factors, a simple CRS scheme could effectively improve the implementation of CIN2+ screening. What's new? Cervical cancer is linked to various risk factors, including persistent infection with strains of high-risk human papillomavirus (HR-HPV). However, whether specific risk factor combinations place some women at greater risk than others is unclear. To find out, the authors of this study combined HR-HPV testing and verified risk factors to develop a cumulative risk score (CRS) scheme. Elevated HR-HPV DNA load was the primary predictor for cervical intraepithelial neoplasia grade 1 (CIN1) and grade 2 (CIN2), but other factors, such as marital status and smoking, also influenced risk-scoring. The CRS scheme was especially useful for CIN2+ screening.
KW - cervical cancer screening
KW - cervical intraepithelial neoplasia
KW - human papillomavirus
KW - risk evaluation
KW - risk-scoring scheme
UR - http://www.scopus.com/inward/record.url?scp=84922276267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922276267&partnerID=8YFLogxK
U2 - 10.1002/ijc.28982
DO - 10.1002/ijc.28982
M3 - Article
C2 - 24841989
AN - SCOPUS:84922276267
SN - 0020-7136
VL - 136
SP - 340
EP - 349
JO - International Journal of Cancer
JF - International Journal of Cancer
IS - 2
ER -